[an error occurred while processing this directive] | ����Ƥ���Բ�ѧ��־ 0, () 355-357 DOI: ISSN: 2096-5540 CN: 32-1880/R | ||||||||||||||||||||||||||||||||||||||||||||||||||||
����Ŀ¼ | ����Ŀ¼ | ������� | ������ [��ӡ��ҳ] [�ر�] | |||||||||||||||||||||||||||||||||||||||||||||||||||||
���� |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
�����Ķ�Ƥ����Ⱦ�ı������� | |||||||||||||||||||||||||||||||||||||||||||||||||||||
��ѧ��1, Francois Niyonsaba2, Ƚ��ƽ1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
1. �Ĵ���ѧ����ҽԺƤ���Բ��� �ɶ� 610041; | |||||||||||||||||||||||||||||||||||||||||||||||||||||
ժҪ��
Ƥ��Ƶ���뻷���е�����Ӵ���������Ⱦ,�����ӿ�����������Ҫ���á����������ӿ�������Ҫ���������غ�cathelicidin���18000���������ӿ�������������LL-37��Ϊ��,���������γ�ϸ�����������������1��2��3��LL-37�Ŀ��������ԺͶ�Ƥ���ı������á� | |||||||||||||||||||||||||||||||||||||||||||||||||||||
�ؼ����� ��������,�� �������� ������ ������ | |||||||||||||||||||||||||||||||||||||||||||||||||||||
1. �Ĵ���ѧ����ҽԺƤ���Բ��� �ɶ� 610041; | |||||||||||||||||||||||||||||||||||||||||||||||||||||
1. �Ĵ���ѧ����ҽԺƤ���Բ��� �ɶ� 610041; | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Abstract: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Keywords: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
�ո����� 2005-03-22 ������ ����淢������ | |||||||||||||||||||||||||||||||||||||||||||||||||||||
DOI: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
������Ŀ: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
ͨѶ����: Ƚ��ƽ,E-mail:ranyuping@hotmail.com | |||||||||||||||||||||||||||||||||||||||||||||||||||||
�����: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
�ο����ף� | |||||||||||||||||||||||||||||||||||||||||||||||||||||
[1] Lehrer RI, Ganz T. Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol, 1999, 11:23-27. [2] Schneider J J, Unholzer A, Schaller M, et al. Human defensins. J Mol Med, 2005, 83:587-595. [3] Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol, 2004, 75:39-48. [4] Bensch KW, Raida M, Magert HJ, et al. hBD-1:a novel beta-defensin from human plasma. FEBS Lett, 1995, 368:331-335. [5] Valore EV, Park CH, Quayle AJ, et al. Human beta-defensin-1:an antimicrobial peptide of urogenital tissues. J Clin Invest, 1998, 101:1633-1642. [6] Chung WO, Dale BA. Innate immune response of oral and foreskin keratinocytes:utilization of different signaling pathways by various bacterial species. Infect Immun, 2004, 72:352-358. [7] Harder J, Bartels J, Christophers E, et al. A peptide antibiotic from human skin. Nature, 1997, 387:861. [8] Harder J, Meyer-Hoffert U, Teran LM, et al. Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol, 2000, 22:714-721. [9] Duits LA, Nibbering PH, van Strijen E, et al. Rhinovirus increases human beta-defensin-2 and-3 mRNA expression in cultured bronchial epithelial cells. FEMS Immunol Med Microbiol, 2003, 38:59-64. [10] Dunsche A, Acil Y, Dommisch H, et al. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur J Oral Sci, 2002, 110:121-124. [11] Harder J, Bartels J, Christophers E, et al. Isolation and characteri zation of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem, 2001, 276:5707-5713. [12] Murakami M, Ohtake T, Dorschner RA, et al. Cathelicidin anti-mi crobial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol, 2002, 119:1090-1095. [13] Murakami M, Dorschner RA, Stern LJ, et al. Expression and secre tion of cathelicidin antimicrobial peptides in murine mammary glands and human milk. Pediatr Res, 2005, 57:10-15. [14] Erdag G, Morgan JR. Interleukin-1alpha and interleukin-6 enhance the antibacterial properties of cultured composite keratinocyte grafts. Ann Surg, 2002, 235:113-124. [15] Liu L, Zhao C, Heng HH, et al. The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes:two peptide families with differing disulfide topology share a common ancestry. Genomics, 1997, 43:316-320. [16] Oren Z, Lerman JC, Gudmundsson GH, et al. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes:relevance to the molecular basis for its non-cell-selec tive activity. Biochem J, 1999, 341:501-513. [17] Schibli DJ, Hunter HN, Aseyev V, et al. The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus. J Biol Chem, 2002, 277:8279-8289. [18] Sahly H, Schubert S, Harder J, et al. Burkholderia is highly resistant to human Beta-defensin 3.Antimicrob Agents Chemother, 2003, 47:1739-1741. [19] Johansson J, Gudmundsson GH, Rottenberg ME, et al. Conformation-dependent antibacterial activity of the naturally occurring hu man peptide LL-37. J Biol Chem, 1998, 273:3718-3724. [20] Niyonsaba F, Someya A, Hirata M, et al. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D (2) production from mast cells. Eur J Immunol, 2001, 31:1066-1075. [21] Yang D, Chertov O, Oppenheim JJ. The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cell Mol Life Sci, 2001, 58:978-989. [22] Niyonsaba F, Iwabuchi K, Someya A, et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology, 2002, 106:20-26. [23] Niyonsaba F, Iwabuchi K, Matsuda H, et al. Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol, 2002, 14:421-426. [24] Nomura I, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol, 2003, 171:3262-3269. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
������������� | |||||||||||||||||||||||||||||||||||||||||||||||||||||
1����ѧ��, Francois Niyonsaba, Ƚ��ƽ.�����Ķ�Ƥ����Ⱦ�ı�������[J]. ����Ƥ���Բ�ѧ��־, 0,(): 355-357 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
2����ѧ��, Francois Niyonsaba, Ƚ��ƽ.�����Ķ�Ƥ����Ⱦ�ı�������[J]. ����Ƥ���Բ�ѧ��־, 2005,31(6): 355-357 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
�������� (��ע��:��վʵ�������Ը�, �벻Ҫ������ѧ���ص�����!�������ݲ�����վ�۵�.) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2008 by ����Ƥ���Բ�ѧ��־ |